Is the growing use of GLP-1s reshaping ideas of Black beauty?

Its author writes from a Sudanese upbringing in which fuller bodies could carry affirmation rather than stigma.

The essay does not deny the possible health value of medicines developed for diabetes. Instead, it asks whether access to them can arrive alongside a narrower ideal of femininity, especially where private prescriptions make thinness look like both a beauty trend and a class signal.

Reports of growing use in South Africa, Ghana, and Kenya are presented as part of that status shift. A global drug market does not land on a blank cultural slate; it enters existing ideas about health, aspiration, and belonging.

Celebrity visibility is the sharper pressure point. The author reads high-profile use and advertising as a new kind of permission, while also insisting that individual choices do not settle the wider question of whose bodies are treated as acceptable.

The unresolved tension is not whether people may use medication. It is whether a tool that can matter for health will also make culturally specific room for body variation harder to hold onto.

Read the full story at The Guardian ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.